Moreover, in vitro studies have confirmed that adiponectin can inhibit tumor growth by activating AMP-activated protein kinase (AMPK) and inhibiting the mammalian rapamycin target (mTOR) pathway, validating the role of obesity in TFE3-RCC [30–32]. Here, ADIPOQ is linked to renal cell carcinoma.